Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease (2013)
- Authors:
- USP affiliated authors: GATTAZ, WAGNER FARID - FM ; FORLENZA, ORESTES VICENTE - FM
- Unidade: FM
- DOI: 10.1590/1516-4446-2012-3505
- Subjects: BIOMARCADORES (USO DIAGNÓSTICO); TRANSTORNOS COGNITIVOS; DEMÊNCIA (DIAGNÓSTICO); DOENÇA DE ALZHEIMER (DIAGNÓSTICO); PROTEÍNAS
- Language: Inglês
- Imprenta:
- Source:
- Título: Revista brasileira de psiquiatria
- ISSN: 1516-4446
- Volume/Número/Paginação/Ano: v. 35, n. 3 p. 284-294, 2013
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
- Licença: other-oa
-
ABNT
FORLENZA, Orestes V. et al. Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease. Revista brasileira de psiquiatria, v. 35, n. 3 p. 284-294, 2013Tradução . . Disponível em: https://doi.org/10.1590/1516-4446-2012-3505. Acesso em: 11 jan. 2026. -
APA
Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Stella, F., & Gattaz, W. (2013). Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease. Revista brasileira de psiquiatria, 35( 3 p. 284-294). doi:10.1590/1516-4446-2012-3505 -
NLM
Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W. Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease [Internet]. Revista brasileira de psiquiatria. 2013 ; 35( 3 p. 284-294):[citado 2026 jan. 11 ] Available from: https://doi.org/10.1590/1516-4446-2012-3505 -
Vancouver
Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W. Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease [Internet]. Revista brasileira de psiquiatria. 2013 ; 35( 3 p. 284-294):[citado 2026 jan. 11 ] Available from: https://doi.org/10.1590/1516-4446-2012-3505 - Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
- Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype
- Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression
- Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
- Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
- Inhibition of phospolipase A2 modulates glycogen synthase activity and tau phosphorylation in primary cultures of cortical and hippocampal neurons
- Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study
- Interleukin-1β Serum Levels is Increased in Antidepressant-Free Elderly Depressed Patients
- Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease
- Diagnosis and biomarkers of predementia in Alzheimer’s disease
Informações sobre o DOI: 10.1590/1516-4446-2012-3505 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
